Cinclus Pharma Holding AB (FRA:J8P) FFO


FRA:J8P Cinclus Pharma Holding AB FRA:J8P
6 GF Score
Price €0.96
! 3 Warning Signs
View Full Analysis

What is Cinclus Pharma Holding AB FFO?

FFO (Funds from operations) only applies to REITs.

FRA:J8P
6GF Score
Cinclus Pharma Holding AB FRA:J8P
FFO is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Cinclus Pharma Holding AB Business Description

Other Exchanges CINPHA:Sweden
Address Kungsbron 1, Stockholm, SWE, SE-111 22
Cinclus Pharma Holding AB is a Swedish clinical-stage pharmaceutical company focused on developing small-molecule treatments for gastric acid-related diseases. Its candidate, linaprazan glurate, is being developed for the treatment of severe gastroesophageal reflux disease, including erosive forms. The company is also developing a dual therapy treatment with an antibiotic targeting Helicobacter pylori, a bacterium found in the gastric and duodenal mucosa. Its primary target population consists of patients with severe erosive gastroesophageal reflux disease, where current treatment options are limited. It operates in Switzerland, Sweden, and the Czech Republic, with the majority of revenue from the Czech Republic.
6GF Score

Get the complete analysis for FRA:J8P

FFO is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.96
Price